Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

By Lihong Liu, Pengfei Wang, M. Nair, Jian Yu, M. Rapp, Qian Wang, Yang Luo, J. Chan, V. Sahi, A. Figueroa and 14 more. 2020

1,353 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 (2020, neutral): “These findings showed that the RBD is a prime target of neutralizing Abs upon natural CoV infection, in agreement with other reports of the isolation of RBD-targeted neutralizing Abs from COVID-19 convalescent patients (Barnes et al., 2020; Brouwer et al., 2020; Liu et al., 2020; Robbiani et al., 20”
Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape (2021, background): “Sequences from other long term 378 infections from individuals AM (18) MA-JL (MA) (19) and a MSK cohort (M) with individuals 2, 3, 4, 6, 8, 379 11, 13 (13) Letters (A&B) designate different variants from the same patient.”
Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies (2021, background): “…escape mutants with reduced neutralization sensitivity (Andreano et al., 2020; Weisblum et al., 2020) , or characterizing the antigenic effects of specific mutations such as those observed in circulating viral isolates (Kemp et al., 2020b; Li et al., 2020; Liu et al., 2020b; Thomson et al., 2020) .”